Findings showed that when compared with placebo, treatment with finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for ...

Canagliflozin, an oral SGLT2 inhibitor, thus becomes the third diabetes drug approved for CV risk reduction in this population. Another SGLT2 inhibitor, empagliflozin (Jardiance, Lilly and ...

Just two days before Amarin faces a pivotal FDA advisory committee to expand its label for fish-oil derivative Vascepa, the FDA has some questions about the key trial's placebo control—namely, whet ...

Back to Healio The FDA issued a draft guidance recommending that labels of over-the-counter aspirin using any CV-related imagery be accompanied by a statement reminding consumers to speak to a ...

That didn’t take long. | Just a few days after unveiling new cardiovascular data for long-acting insulin Tresiba, Novo Nordisk has made moves to get them added to the medication’s label.